ilmscore | 3 stocks with business turnaround from loss to profits

3 stocks with business turnaround from loss to profits

Published: 2026-01-11
Status: Analyzed

Predictions from this Video

Total: 8
Correct: 0
Incorrect: 0
Pending: 8
Prediction
Topic
Status
Black Buck Limited's 'Super Loads' business segment plans to expand from 4 hubs to 14-15 hubs within the next six months (by July 2026).
"Super Loads plans to scale from four hubs to 14 to 15 hubs in the next six months, providing long-term growth visibility."
Black Buck Limited
Pending
GMR Airports management expects double-digit passenger growth.
"So we expect 8% to be a little bit more conservative. I think a double digit growth is given."
GMR Airports Limited
Pending
GMR Airports expects structurally lower depreciation due to accounting policy alignment, leading to an annual benefit of Rs 150 crore, and interest costs are expected to slightly reduce in the coming quarters due to refinancing.
"Management also stated in the recent September quarter that depreciation is going to be structurally lower due to accounting policy alignment. The annual benefit of around Rs 150 crore and the full impact of refinancing can slightly reduce the interest cost in the coming quarters."
GMR Airports Limited
Pending
GMR Airports' Bhogapuram Airport is expected to become operational within the next 9 to 12 months (by Oct 2026 - Jan 2027).
"GMR Airports Bhogapuram Airport, which is 87.5% complete and will be operational in the next 9 to 12 months"
GMR Airports Limited
Pending
Wockhardt management aims to build a global organization to maintain leadership in antibiotic drug discovery in the next decade (by 2035).
"So we are now in a process of building a global organization to take the leadership in the next decade also."
Wockhardt Limited
Pending
Wockhardt plans to launch its 'Genic Drugs' in India in the second half of FY26 (by March 2026) and globally in FY27 (April 2026 - March 2027).
"Genic Drugs plans to launch India in the second half and global in FY27."
Wockhardt Limited
Pending
Wockhardt aims for 20-25% growth in its biotech and diabetes biosimilar segments by doubling capacity within the next 3 years (by January 2029).
"In the biotech and diabetes biosimilar segments, the company is targeting 20 to 25% growth by doubling its capacity in the next 3 years."
Wockhardt Limited
Pending
Wockhardt, as one of only three players, is poised to benefit from new human insulin market opportunities in India (worth Rs 450 crore) and emerging markets (worth $157 million), following the phase-out of Novo Nordisk's 'Novo Nodex'.
"The phase-out of Novo Nodex has opened up opportunities worth $450 crore in India and $157 million in emerging markets. In which only three players including work hard can benefit."
Wockhardt Limited
Pending